Project Grant R21NS135514
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $160,500 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to Children's Hospital Medical Center in Cincinnati, Ohio. The grant supports research to investigate the epigenetic mechanisms underlying neurodevelopmental defects in Menke-Hennekam Syndrome, a rare genetic disorder caused by mutations in the EP300 gene. The project aims to (1) identify maturation and...
- Northwestern University received a $420,790 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) on September 15, 2023. The funding will support a research project titled "Deep Mutational Scanning of CHD2 for Variant Interpretation in Neurodevelopmental Disorders". This effort aims to develop a high-throughput assay to evaluate the functional...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under CFDA 93.853 "Extramural Research Programs in the Neurosciences and Neurological Disorders", provides $230,904 to Boston Children's Hospital from January 1, 2025 to December 31, 2029. The award will support research to identify novel genetic causes of infantile epilepsies and evaluate the impact of genetic diagnosis on patient outcomes and families. Key objectives include applying...
- This Project Grant award of $241,380 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) aims to advance the understanding of neurodevelopmental disorders (NDDs) and develop innovative therapies. The research program, led by researchers at Boston Children's Hospital, will use single-cell epigenomic technologies to link pathogenic variants in chromatin regulators, such as...
- This Project Grant award of $596,146.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) is funding research by The Children's Hospital of Philadelphia (CHOP) to investigate the developmental mechanisms behind temperature-sensitive seizures. The goal is to develop a comprehensive understanding of how febrile seizures, which are the most common type of seizures in children,...
- This Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), will fund research to investigate the impact of coding and non-coding mutations in the ARID1B gene on neurodevelopmental disorders (NDDs). The $294,408 award, spanning November 2024 to May 2027, will enable Emory University to characterize ARID1B haploinsufficient mice at the...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a 5-year, $220,050 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The Children's Hospital of Philadelphia Research Institute. The grant aims to advance clinical trial readiness for SYNGAP1-related disorder (SYNGAP1-RD), a rare monogenic epilepsy associated with severe neurodevelopmental issues. The research project will prospectively follow a cohort...
- This federal Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), is focused on identifying novel noncoding genetic mechanisms that contribute to developmental disorders. The $499,055.48 award, with a project period from November 1, 2024 to October 31, 2027, will fund research led by Dr. Chelsea Lowther at the Icahn School of Medicine at Mount...
- This $147,486 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will support research to gain deeper insight into the pathophysiology of SCN3A-related neurodevelopmental disorder (SCN3A-NDD) and advance the development of effective therapeutic interventions. The research will utilize a novel mouse model of SCN3A-NDD to: 1) evaluate the...
- This Project Grant award of $743,776 from the National Institute of Neurological Disorders and Stroke (NINDS, CFDA 93.853) supports research to determine whether and when ablating mutant cells that cause epilepsy can reverse the disease in mouse models of mTOR pathway disorders. The research aims to advance the development of AAV-mediated gene therapy approaches to treat intractable epilepsy caused by mTOR pathway mutations. This work builds upon almost two decades of the recipient...
UNCOVERING MECHANISMS OF CHD2-ASSOCIATED EPILEPSY USING HUMAN CORTICAL ORGANOIDS - PROJECT SUMMARY/ABSTRACT MUTATIONS IN CHD2 GENE ARE ASSOCIATED WITH DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY (DEE), A SEVERE FORM OF CHILDHOOD EPILEPSY. CHD2 BELONGS TO THE CHROMODOMAIN HELICASE DNA BINDING (CHD) FAMILY OF ATP DEPENDENT CHROMATIN REMODELERS KNOWN TO PLAY A CRITICAL ROLE IN NEURODEVELOPMENT VIA CHROMATIN ORGANIZATION AND GENE REGULATION; AND IS THE ONLY ONE AMONG 9 OTHER CHD (CHD1-CHD9) FAMILY PROTEINS THAT CAUSES A BRAIN RESTRICTED PHENOTYPE SUGGESTING ITS NON-REDUNDANT ROLE IN NEURODEVELOPMENTAL DISORDERS. STUDIES IN MICE HAVE SHOWN THAT KNOCKDOWN OF CHD2 IN EMBRYONIC CORTEX DECREASES THE AMPLIFICATION OF RADIAL GLIAL CELLS (RGCS) AND PROMOTES THE GENERATION OF INTERMEDIATE PROGENITOR CELLS (IPS). MOREOVER, CHD2+/- MICE, THE ONLY KNOWN HETEROZYGOUS MOUSE LINE TO DATE TO MIMIC CHD2 HAPLOINSUFFICIENCY IN HUMAN, EXHIBITS REDUCED NUMBER OF GABAERGIC INTERNEURONS, DISRUPTS CELL PROLIFERATION IN THE DEVELOPING FOREBRAIN AND DISPLAYS A SHIFT IN NEURONAL EXCITABILITY. ADDITIONALLY, A STUDY USING 2D CULTURE OF MEDIAL GANGLIONIC EMINENCE (MGE) LIKE PROGENITORS AND CORTICAL INTERNEURONS DERIVED FROM HUMAN EMBRYONIC STEM CELLS (HESCS) HAS SHOWN THAT CHD2 DEFICIENCY IMPAIRS INTERNEURON DEVELOPMENT AND ALTERS ITS FUNCTIONS. THOUGH THESE STUDIES HAVE BEEN CRITICAL TOWARDS OUR FUNDAMENTAL UNDERSTANDING OF THE ROLE OF CHD2 IN NEURODEVELOPMENT, NEITHER MICE NOR 2D NEURONAL CULTURES REPRESENT THE FULL BREADTH OF HUMAN BRAIN DEVELOPMENT AND LEAVE A CRITICAL GAP IN KNOWLEDGE ABOUT THE HUMAN SPECIFIC CELLULAR AND MOLECULAR MECHANISMS ASSOCIATED WITH CHD2 MUTATION. TO FILL THIS GAP, WE PROPOSE TO USE PATIENT DERIVED INDUCED PLURIPOTENT STEM CELLS (IPSCS) DIFFERENTIATED INTO HUMAN CORTICAL ORGANOIDS (HCO). HCO CLOSELY MIMIC THE DEVELOPMENT OF HUMAN FOREBRAIN AND IS AN INNOVATIVE MODEL SYSTEM TO STUDY PATIENT SPECIFIC CELLULAR AND MOLECULAR MECHANISMS UNDERLYING A DISEASE-CAUSING MUTATION. BASED ON OUR PRELIMINARY DATA USING SINGLE CELL RNA SEQUENCING (SCRNA-SEQ) IN HCO, WE HYPOTHESIZE THAT CHD2 MUTATION LEADS TO DEFECTS IN CORTICAL PROGENITOR PROLIFERATION AND DIFFERENTIATION DURING NEURODEVELOPMENT CONTRIBUTING TO ALTERED CORTICAL CIRCUITRY AND EPILEPSY. TO TEST OUR HYPOTHESIS, WE WILL 1) DETERMINE THE CELLULAR IMPACT OF CHD2 MUTATION IN CORTICAL DEVELOPMENT AND EPILEPSY USING IMMUNOHISTOCHEMISTRY (AIM 1) AND 2) DELINEATE THE MOLECULAR MECHANISMS OF CHD2 MUTATION IN NEURODEVELOPMENT AND EPILEPSY BY PERFORMING MULTIOME ANALYSIS (SCRNA-SEQ + SCATAC-SEQ) (AIM 2). THE PROPOSED STUDY WILL NOT ONLY INCREASE OUR UNDERSTANDING OF THE CHILDHOOD EPILEPSY AND RELATED NEURODEVELOPMENTAL DISORDERS BUT ALSO PROVIDE GREATER INSIGHT INTO NOVEL IN VITRO CORTICAL ORGANOID MODELS TO STUDY A NUMBER OF PATHOGENIC VARIANTS. TO OUR KNOWLEDGE, THIS IS THE FIRST TIME THAT PATIENT DERIVED IPSCS DIFFERENTIATED INTO CORTICAL ORGANOIDS HAVE BEEN PROPOSED TO STUDY CHD2 MUTATION IN HUMANS, AND IN OUR MODEL SYSTEM, WE WILL BE ABLE TO IDENTIFY PREVIOUSLY UNKNOWN CELLULAR AND MOLECULAR MECHANISMS UNDERLYING CHD2 ASSOCIATED EPILEPSY PAVING THE WAY FOR DEVELOPMENT OF BETTER THERAPEUTIC INTERVENTION STRATEGIES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 9/25/25 | ||
| Not listed | $412.5k | 9/14/23 |